Research

The Kwon Research Group pioneers advanced polymeric nanotechnology to revolutionize the delivery and effectiveness of anticancer and antifibrotic drugs. By engineering polymeric nanoparticles and polymer-drug conjugates, our team enhances drug circulation time, boosts therapeutic potency, and minimizes toxicity—addressing the major limitations of current potent yet toxic treatments.

Our mission is to design safe, effective nanomedicines that specifically target cancer and fibrosis, with a strong emphasis on clinical translation. Through innovative research and collaboration, we strive to bring these next-generation therapies from the laboratory to human clinical trials, with the ultimate goal of saving lives and improving patient outcomes.